Arachidonic Acid Release from Rat Leydig Cells: the Involvement of G Protein, Phospholipase A2 and Regulation of CAMP Production
Overview
Authors
Affiliations
We have previously demonstrated that the release of arachidonic acid (AA) from human chorionic gonadotropin (hCG)-stimulated Leydig cells occurs in a dose- and time-dependent manner. In addition, the amount of AA released was dependent on the hormone-receptor interaction and the concentration of LH-hCG binding sites on the cell surface. The present study was conducted to evaluate the involvement of phospholipase A(2) (PLA(2)) and G proteins in AA release from hormonally stimulated rat Leydig cells, and the possible role of this fatty acid in cAMP production. Cells were first prelabelled with [(14)C]AA to incorporate the fatty acid into cell phospholipids, and then treated in different ways to evaluate AA release. hCG (25 mIU) increased the release of AA to 180+/-12% when compared with AA released from control cells, arbitrarily set as 100%. Mepacrine and parabromophenacyl bromide (pBpB), two PLA(2) inhibitors, decreased the hormone-stimulated AA release to 85+/-9 and 70+/-24% respectively. Conversely, melittin, a PLA(2) stimulator, increased the release of AA up to 200% over control. The inhibitory effect of mepacrine on the release of AA was evident in hCG-treated Leydig cells, but not in the melittin-treated cells. To determine if the release of AA was also mediated through a G protein, cells were first permeabilized and subsequently treated with pertussis toxin or GTPgammaS, a non-hydrolyzable analog of GTP. Results demonstrate that GTPgammaS was able to induce a similar level of the release of AA as hCG. In addition, pertussis toxin completely abolished the stimulatory effect of hCG on the release of AA, indicating that a member of the G(i) family was involved in the hCG-dependent release of AA. Cells treated with PLA(2) inhibitors did not modify cAMP production, but exogenously added AA significantly reduced cAMP production from hCG-treated Leydig cells, in a manner dependent on the concentration of AA and hCG. Results presented here suggest an involvement of PLA(2) and G proteins in the release of AA from hCG-stimulated Leydig cells, and under particular conditions, regulation of cAMP production by this fatty acid in these cells.
Basic Leucine Zipper Transcription Factors as Important Regulators of Leydig Cells' Functions.
Martin L, Nguyen H Int J Mol Sci. 2022; 23(21).
PMID: 36361676 PMC: 9658026. DOI: 10.3390/ijms232112887.
Shamhari A, Abd Hamid Z, Budin S, Shamsudin N, Taib I Biomedicines. 2021; 9(11).
PMID: 34829973 PMC: 8615890. DOI: 10.3390/biomedicines9111744.
Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism.
Peak T, Haney N, Wang W, DeLay K, Hellstrom W World J Stem Cells. 2016; 8(10):306-315.
PMID: 27822338 PMC: 5080638. DOI: 10.4252/wjsc.v8.i10.306.
Keith D, Eshleman A, Janowsky A Eur J Pharmacol. 2010; 650(2-3):501-10.
PMID: 20969853 PMC: 3125126. DOI: 10.1016/j.ejphar.2010.10.023.
Leydig cells: From stem cells to aging.
Chen H, Ge R, Zirkin B Mol Cell Endocrinol. 2009; 306(1-2):9-16.
PMID: 19481681 PMC: 2749461. DOI: 10.1016/j.mce.2009.01.023.